Literature DB >> 24101130

Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

Maike F Dohrn1, Christoph Röcken, Jan L De Bleecker, Jean-Jacques Martin, Matthias Vorgerd, Peter Y Van den Bergh, Andreas Ferbert, Katrin Hinderhofer, J Michael Schröder, Joachim Weis, Jörg B Schulz, Kristl G Claeys.   

Abstract

Familial amyloid polyneuropathy (FAP) is a progressive systemic autosomal dominant disease caused by pathogenic mutations in the transthyretin (TTR) gene. We studied clinical, electrophysiological, histopathological, and genetic characteristics in 15 (13 late-onset and two early-onset) patients belonging to 14 families with polyneuropathy and mutations in TTR. In comparison, we analysed the features of nine unrelated patients with an idiopathic polyneuropathy, in whom TTR mutations have been excluded. Disease occurrence was familial in 36 % of the patients with TTR-associated polyneuropathy and the late-onset type was observed in 86 % (mean age at onset 65.5 years). Clinically, all late-onset TTR-mutant patients presented with distal weakness, pansensory loss, absence of deep tendon reflexes, and sensorimotor hand involvement. Afferent-ataxic gait was present in 92 % leading to wheelchair dependence in 60 % after a mean duration of 4.6 years. Autonomic involvement was observed in 60 %, and ankle edema in 92 %. The sensorimotor polyneuropathy was from an axonal type in 82 %, demyelinating or mixed type in 9 % each. Compared to the TTR-unmutated idiopathic polyneuropathy patients, we identified rapid progression, early ambulatory loss, and autonomic disturbances, associated with a severe polyneuropathy as red flags for TTR-FAP. In 18 % of the late-onset TTR-FAP patients, no amyloid was found in nerve biopsies. Further diagnostic pitfalls were unspecific electrophysiology, and coincident diabetes mellitus (23 %) or monoclonal gammopathy (7 %). We conclude that a rapid disease course, severely ataxic gait, hand involvement, and autonomic dysfunction are diagnostic hallmarks of late-onset TTR-FAP. Genetic analysis should be performed even when amyloid deposits are lacking or when polyneuropathy-causing comorbidities are concomitant.

Entities:  

Mesh:

Year:  2013        PMID: 24101130     DOI: 10.1007/s00415-013-7124-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  44 in total

Review 1.  Aboard transthyretin: From transport to cleavage.

Authors:  Márcia A Liz; Fernando M Mar; Filipa Franquinho; Mónica M Sousa
Journal:  IUBMB Life       Date:  2010-06       Impact factor: 3.885

2.  Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy.

Authors:  Haruki Koike; Yukio Ando; Mitsuharu Ueda; Yuichi Kawagashira; Masahiro Iijima; Junko Fujitake; Michiyuki Hayashi; Masahiko Yamamoto; Eiichiro Mukai; Tomohiko Nakamura; Masahisa Katsuno; Naoki Hattori; Gen Sobue
Journal:  J Neurol Sci       Date:  2009-08-25       Impact factor: 3.181

3.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

Authors:  D R Jacobson; R D Pastore; R Yaghoubian; I Kane; G Gallo; F S Buck; J N Buxbaum
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

4.  Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.

Authors:  A Quintas; D C Vaz; I Cardoso; M J Saraiva; R M Brito
Journal:  J Biol Chem       Date:  2001-04-16       Impact factor: 5.157

5.  Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation.

Authors:  M M Sousa; S D Yan; D Stern; M J Saraiva
Journal:  Lab Invest       Date:  2000-07       Impact factor: 5.662

6.  Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).

Authors:  G Holmgren; L Steen; J Ekstedt; C G Groth; B G Ericzon; S Eriksson; O Andersen; I Karlberg; G Nordén; M Nakazato
Journal:  Clin Genet       Date:  1991-09       Impact factor: 4.438

7.  Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form.

Authors:  Haruki Koike; Ken-ichiro Misu; Shu-ichi Ikeda; Yukio Ando; Masamitsu Nakazato; Eiko Ando; Masahiko Yamamoto; Naoki Hattori; Gen Sobue
Journal:  Arch Neurol       Date:  2002-11

8.  Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal.

Authors:  Isabel Conceição; Mamede De Carvalho
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

9.  In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE).

Authors:  Filipe Almeida Monteiro; Isabel Cardoso; Mónica Mendes Sousa; Maria João Saraiva
Journal:  FEBS Lett       Date:  2006-05-15       Impact factor: 4.124

10.  Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy.

Authors:  F A Monteiro; M M Sousa; I Cardoso; J Barbas do Amaral; A Guimarães; M J Saraiva
Journal:  J Neurochem       Date:  2006-03-03       Impact factor: 5.372

View more
  26 in total

1.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Authors:  Peter J Dyck; John C Kincaid; P James B Dyck; Vinay Chaudhry; Namita A Goyal; Christina Alves; Hayet Salhi; Janice F Wiesman; Celine Labeyrie; Jessica Robinson-Papp; Márcio Cardoso; Matilde Laura; Katherine Ruzhansky; Andrea Cortese; Thomas H Brannagan; Julie Khoury; Sami Khella; Márcia Waddington-Cruz; João Ferreira; Annabel K Wang; Marcus V Pinto; Samar S Ayache; Merrill D Benson; John L Berk; Teresa Coelho; Michael Polydefkis; Peter Gorevic; David H Adams; Violaine Plante-Bordeneuve; Carol Whelan; Giampaolo Merlini; Stephen Heitner; Brian M Drachman; Isabel Conceição; Christopher J Klein; Morie A Gertz; Elizabeth J Ackermann; Steven G Hughes; Michelle L Mauermann; Rito Bergemann; Karen A Lodermeier; Jenny L Davies; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2017-04-07       Impact factor: 3.217

Review 2.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

3.  Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study.

Authors:  David Adams; Teresa Coelho; Laura Obici; Giampaolo Merlini; Zoia Mincheva; Narupat Suanprasert; Brian R Bettencourt; Jared A Gollob; Pritesh J Gandhi; William J Litchy; Peter J Dyck
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

Review 4.  Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.

Authors:  Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-03-07       Impact factor: 13.654

5.  A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.

Authors:  Anne Schänzer; Christoph Kimmich; Christoph Röcken; Thomas Haverkamp; Isabell Weidner; Till Acker; Heidrun H Krämer
Journal:  J Med Case Rep       Date:  2014-12-04

Review 6.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

Review 7.  Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review.

Authors:  A C Martins; A M Rosa; E Costa; C Tavares; M J Quadrado; J N Murta
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

Review 8.  "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.

Authors:  Isabel Conceição; Alejandra González-Duarte; Laura Obici; Hartmut H-J Schmidt; Damien Simoneau; Moh-Lim Ong; Leslie Amass
Journal:  J Peripher Nerv Syst       Date:  2016-03       Impact factor: 3.494

Review 9.  Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Authors:  Yesim Parman; David Adams; Laura Obici; Lucía Galán; Velina Guergueltcheva; Ole B Suhr; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

Review 10.  Evolving landscape in the management of transthyretin amyloidosis.

Authors:  Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr
Journal:  Ann Med       Date:  2015-11-27       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.